InvestSMART

Acrux Limited (ASX:ACR)

ALERT: Price-sensitive ASX Announcement for ACR
Current share price for ACR : $0.009 -0.002 (-18.18%)+
Announcement
Release
6 Aug 2026 9:02AM
Price at Release
$0.011
Full Release
download
Summary
The investor presentation by Acrux Limited at the Bioshares Biotech Summit on 6 August 2026 detailed their strategy and advancements in female testosterone therapy for treating Hypoactive Sexual Desire Disorder (HSDD). Acrux is focusing on a new Metered Dose Transdermal System (MDTS) applicator that delivers testosterone effectively through the skin. The presentation highlighted the significant market potential for this therapy, emphasizing the global need for female-specific testosterone treatments. Acrux's clinical trials have shown promising results, with a notable increase in satisfactory sexual events for women using the testosterone spray compared to a placebo. The company plans to expand the use of this therapy to address other women's health issues such as cognitive symptoms and premature menopause. Acrux is seeking co-development partnerships to expedite the clinical trial process and product launch. The presentation outlined Acrux's history of innovation in drug delivery technologies and its commitment to addressing unmet needs in women's health.
Key Points
  • Acrux is developing a female testosterone therapy for HSDD using MDTS.
  • Significant market potential for female-specific testosterone treatments.
  • Clinical trials show increased satisfactory sexual events for users.
  • Plans to expand therapy to other women's health issues.
  • Seeking co-development partnerships for expedited product launch.
  • History of innovation in drug delivery technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.